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Abstract
Objective—Long-term follow-up studies documenting maintenance of treatment effects are few 
in adolescent anorexia nervosa (AN). This exploratory study reports relapse from full remission 
and attainment of remission during a four-year open follow-up period using a convenience sample 
of a subgroup of 65% (n=79) from an original cohort of 121 participants who completed a 
randomized clinical trial comparing family based therapy (FBT) and adolescent focused individual 
therapy (AFT).
Method—Follow-up assessments were completed up to four years posttreatment (average of 3.26 
years). Available participants completed the Eating Disorder Examination as well as self-report 
measures of self-esteem and depression at two to four years posttreatment.
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Results—Two participants (6.1%) relapsed (FBT: n = 1, 4.5%; AFT: n = 1, 9.1%), on average 
1.98 years (SD = 0.14) after remission was achieved at one-year follow-up. Ten new participants 
(22.7%) achieved remission (FBT: n = 1, 5.9%; AFT: n = 9, 33.3%). Mean time to remission for 
this group was 2.01 years (SD = 0.82) from one-year follow-up. There were no differences based 
on treatment group assignment in either relapse from full remission or new remission during long-
term follow-up. Other psychopathology was stable over time.
Conclusion—There were few changes in the clinical presentation of participants who were 
assessed at long-term follow-up. These data suggest that outcomes are generally stable 
posttreatment regardless of treatment type once remission is achieved.
Clinical trial registration information—Effectiveness of Family-Based Versus Individual 
Psychotherapy in Treating Adolescents With Anorexia Nervosa; http://www.clinicaltrials.gov/; 
NCT00149786.
Keywords
anorexia nervosa; adolescence; long-term follow-up; family-based treatment; adolescentfocused 
treatment
Introduction
Despite high rates of morbidity and mortality for adolescents with anorexia nervosa(AN),1 
relatively few randomized controlled trials (RCTs) for this patient population have been 
conducted.2-8 Even fewer studies have examined the long-term maintenance of treatment 
effects in RCTs.9-11
Using a relatively low standard for remission (weight >85% of expected body weight 
[EBW]), colleagues at the Maudsley Hospital in London demonstratedremission rate for 
family therapy was stable over time at 90% for both one-year andfive-year follow-up 
assessment.9 In contrast, theyshowed that the remission rate for individual therapy 
significantly improved from 18% atone-year follow-up to 60% at five-year follow-up. 
Nonetheless, the remission rate in family therapy remained superior over that of individual 
therapy. Another four-year follow-up study that compared two doses of family therapy 
found no differences in remission rates by dose. Using various standard definitions of 
remission, rates ranged from 60-90%.11 A study that compared conjoint family therapy to 
separated family therapy found no differences in remission at four-year follow-up (78% and 
90% respectively, using Morgan Russell Categories).10 Taken together these studies suggest 
that longer-term outcome in adolescents who were successfully treated in family therapy are 
likely to be maintained at follow-up regardless of the definition of remission utilized.12-13
The current study examined relapse from remission, with the latter defined as >95% EBW 
for age, height, and gender, and a global Eating Disorder Examination (EDE) score within 
one SD of the community mean of 1.54 for adolescents. The sample was drawn from the 
original cohort of 121 participants in an RCT that compared two manual-based treatments, 
family-based treatment (FBT) and adolescent focused therapy (AFT).6 Based on the findings 
from previous studies showing stability in outcomes over time, we predicted that those who 
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were remitted at one-year follow-up were likely to remain so at longer-term follow-up 
regardless of treatment type received.
Method
Participants and Procedures
The design of the original two-site RCT (The University of Chicago and Stanford 
University) was described in detail in our main report.6 Briefly, 121 adolescents with DSM-
IV AN,14 except for the amenorrhea criterion, were randomized to either FBT or AFT. 
Participants were enrolled if they were 12-18 years of age, lived with parents or legal 
guardians, and were medically stable for outpatient treatment.15 Written informed consent 
was obtained after a study coordinator provided a description of the study to the participant 
and their parents. The institutional review boards of the two clinical sites provided approval 
for the study. The participants in the current study are a convenience sample who agreed to 
provide follow-up at two, three, and four years posttreatment after the original study was 
completed. Participant outcomes at the end of treatment and one-year follow-up have been 
previously reported.6
Treatments
The two manual-based treatments utilized in the original study are described in detail 
elsewhere: AFT16 and FBT.17 Briefly, AFT is an individual therapy and focuses on 
amending eating disorder symptoms in the context of examining common themes in 
adolescent development. FBT, on the other hand, is familyfocused and leverages parental 
support of eating-related behaviors in their child. Participants were seen as outpatients for 24 
contact hours over a one-year period.
Assessments
For the present study, independent assessors not involved in treatment delivery conducted 
assessments at two, three, and four years posttreatment. Utilizing the last available data 
point from two- to four-year follow-up, mean time to long-term follow-up from the end of 
treatment for the full sample was 3.26 years (SD = 1.29; range: 0.87, 5.40). Mean follow-up 
time was comparable between FBT (M = 3.30, SD = 1.33) and AFT (M = 3.21, SD = 1.26). 
Variables examined at these various time points included: 1) weight (percentile body mass 
index [BMI] using Centers for Disease Control and Prevention [CDC] norms for age and 
gender);18 2) eating disorder psychopathology (EDE-Global score);19 3) depressive 
symptoms (Beck Depression Inventory, or BDI);20 4) self-esteem (Rosenberg Self-Esteem 
Scale, or RSES);21 5) obsessivecompulsive features of eating symptoms and behaviors 
(YBC-ED);22 and 6) use of psychiatric medications.
Our main outcome of interest is relapse (defined as meeting study entry weight criteria of 
87% of expected mean BMI for age, height, and gender) from full remission (defined as 
weight greater than or equal to 95% of expected BMI for age, height, and gender and an 
EDE-Global score within 1 SD of community means (i.e., 1.54), and new remissions using 
these same criteria. Secondary outcomes of interest are changes in eating pathology, 
depressive symptoms, self-esteem, and obsessive-compulsive symptoms. The prevalence of 
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other eating disorder diagnoses, mood disorders, and anxiety disorders were also examined 
at long-term follow-up.
Statistical Analyses
SPSS Version 19.0 was used for all analyses. Independent t- and chi-square tests were used 
to compare individuals with and without missing data. Evaluating time to relapse and 
remissionfrom one-year follow-up was performed using survival analyses,23-24 with time 
calculated as the difference between the assessment date at one-year follow-up and the 
assessment date at which the event (i.e., relapse or remission) occurred. For the survival 
curve of time to relapse (27.3%, n=33), participants with missing data (23.1%, n=28) and 
those who were not remitted (49.6%, n=60) at one-year follow-up were excluded. 
Participants with no follow-up data and those who remained recovered at all measured 
follow-up time points were treated as ″censored″ observations, indicating that relapse did 
not occur prior to termination of the measurement period. For the survival curve of time to 
remission (49.6%, n=60), participants with missing data (23.1%, n=28) and those who had 
remitted (27.3%, n=33) at one-year follow-up were excluded. Participants with no follow-up 
data and those who remained nonremitted at all measured follow-up time points were treated 
as ″censored″ observations, indicating that remission did not occur prior to termination of 
the measurement period.
Indicator variables, coded as -.5 and +.5 were created to represent treatment group and 
treatment center. Baseline (i.e., age, duration of illness, psychiatric comorbidity, 
psychotropic medication use, prior hospitalization, %EBW, EDE global score, YBC-ED 
score, and BDI score) and end of treatment (i.e., EDE global score, YBC-ED score, or BDI 
score, %EBW) predictors were examined in separate survival analyses, controlling for the 
effects of treatment group and center. A Cox proportional hazard model was then fitted 
using a log logistic distribution.
Results
Comparison of follow-up sample and non-follow-up sample
One-year follow-up data were available for 77% of the original cohort (93/121). For the 
present longer-term follow-up study, data were available for 65.3% (79/121) of the original 
cohort, i.e., at least one data point two to four years after the end of treatment. Of these, 33 
(41.8%) had only one assessment— 6 (18.2%) at two years, 10 (30.3%) at three years, and 
17 (51.5%) at four years. The sample sizes for follow-ups at two-, three-, and four-year 
follow-ups were 37, 50, and 52. Compared to adolescents who did not complete any long-
term follow-up assessments (i.e., no data available between two- and four-year follow-up), 
those who completed at least one follow-up assessment between two and four years did not 
differ with respect to treatment (FBT versus AFT), site, baseline demographic characteristics 
(i.e., age, gender, racial/ethnic minority, family income, parent education, and intact family), 
or baseline clinical characteristics (i.e., AN subtype, duration of illness, prior hospitalization, 
psychiatric comorbidity, and psychotropic medication use). In addition, they did not differ 
on %EBW or global EDE score at baseline.
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Time to relapse after remission at one-year follow-up
The clinical characteristics of the sample available for analysis at the long-term outcome 
assessment are summarized in Table 1. Taking the last completed assessment from two to 
four years posttreatment, mean %EBW at long-term follow-up was 94.11 (SD = 11.11). 
Eating disorder symptoms (assessed with global EDE score) at long-term follow-up were 
minimal (M = 1.00, SD = 1.25). Approximately one third of participants achieved full 
remission at long-term follow-up (n = 25, 31.6%), while more than a quarter was still 
symptomatic (i.e., %EBW ≤87) at long-term follow-up (n = 21, 26.6%). Using DSM-IV 
diagnoses, two (2.5%) participants met criteria for bulimia nervosa (FBT: n = 1; AFT: n = 
1), and five (6.3%) met criteria for eating disorder not otherwise specified (FBT: n = 1; 
AFT: n = 4). Eight (10.1%) met criteria for a mood disorder (FBT: n = 3; AFT: n = 5), and 
12 (15.2%) met criteria for an anxiety disorder (FBT: n = 6; AFT: n = 6).
For those who had achieved full remission at one-year posttreatment (n=33; n=22 in FBT, 
n=11 in AFT), a survival curve examined time to relapse. Seven participants were dropped 
from the survival curve (21.2%), including six participants with no follow-up data and one 
participant with follow-up data prior to the earliest event in the stratum. The remaining 26 
participants were assessed on average 2.68 years (SD = 0.60) after one-year follow-up. Of 
these, 24 (72.7%) were “censored,” indicating that relapse did not occur prior to termination 
of the measurement period, while two (6.1%) relapsed (FBT: n = 1, 4.5%; AFT: n = 1, 
9.1%). For those who were remitted at one-year follow-up, mean time to relapse was 1.98 
years (SD = 0.14) after one-year follow-up.
The treatment group by center interaction was not included in the model due to non-
convergence; therefore, only the main effects for treatment group and center were included 
in the main survival analysis. There was no significant main effect of treatment (Wald chi-
square=0.320, df=1, p=.57, OR = 0.443) or center (Wald chi-square=0.001, df=1, p=.98, OR 
= 0.967; see Figure 1). Controlling for treatment, there were no significant effects (main 
effects or interactions with treatment) for age, duration of illness, initial and end of treatment 
%EBW, initial EDE global score, initial YBC-ED score, and initial BDI score (p's > >.10). 
The impact of EDE global score, YBC-ED score, and BDI score at EOT on time to relapse 
could not be examined due to model non-convergence. Additionally, the impact of 
psychiatric comorbidity, psychotropic medication use, and prior hospitalization could not be 
examined due to model non-convergence.
Time to remission from one-year follow-up
For those who had not achieved full remission at one-year posttreatment (n=60; n=22 in 
FBT, n=38 in AFT), a survival curve examined time to remission. Sixteen participants were 
not included in the survival curve (26.7%), including 15 participants with no follow-up data 
and one participant with follow-up data prior to the earliest event in the stratum. The 
remaining 44 participants were assessed on average 2.49 years (SD = 0.75) after one-year 
follow-up. Of these, 35 (79.5%) were “censored,” indicating that full remission did not 
occur prior to termination of the measurement period, while ten new participants (22.7%) 
achieved first time remission (FBT: n = 1, 5.9%; AFT: n = 9, 33.3%). For those who were 
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not remitted at one-year follow-up, mean time to remission was 2.01 years (SD = 0.82) after 
one-year follow-up.
The treatment group by center interaction was not included in the model due to non-
convergence; therefore, only the main effects for treatment group and center were included 
in the main survival analysis. There were no significant main effects for treatment (Wald 
chi-square=3.047, df=1, OR = 0.156, p=.081) or center (Wald chi-square=0.282, df=1, OR = 
1.435, p=.60; see Figure 2). Controlling for treatment, there were no significant effects 
(main effects or interactions with treatment) for duration of illness, initial %EBW, initial 
EDE global score, initial YBC-ED score, or initial BDI score (p's >.10). There were also no 
significant effects (main effects or interactions with treatment) for EDE global score, YBC-
ED score, or BDI score at the end of treatment (p's >.10). The impact of age, psychiatric 
comorbidity, psychotropic medication use, prior hospitalization, and %EBW at end of 
treatment could not be examined due to model non-convergence. Figure 2 depicts time to 
remission, where the vertical axis represents the survival function, or the proportion of 
adolescents who were not in remission.
Discussion
This exploratory follow-up study examined relapse and remission rates in adolescents with 
AN using a convenience sub-sample available for assessment from a sample treated in an 
RCT comparing FBT to AFT. We predicted that there would be stability in terms of 
remission status from the initial one-year follow-up through the follow-up period, regardless 
of treatment group.
Indeed, only two participants who were remitted at the one year follow-up point relapsed 
(one in each treatment group). This finding supports our main hypothesis about the stability 
of remission, once achieved, regardless of treatment assignment. Furthermore, an additional 
one-quarter of participants that were not remitted at one year follow-up achieved remission 
during longer term follow-up. Findings from the present study also indicate that 
approximately one third of participants were remitted at long-term follow-up, which is 
around the same proportion that was remitted at one-year follow-up across treatment groups. 
Eating disorder symptom severity and %EBW also remained relatively stable over time. 
Moreover, there were low rates of bulimia nervosa, other eating disorders, and mood or 
anxiety disorders at follow-up. Taken together, treatment outcomes were relatively stable 
over time in the subsample used in this study.
Several strengths as well as limitations to this study are worth mentioning. Our initial study 
was designed with adequate power to detect a difference on our main outcome variable (i.e., 
remission). Participants were randomized to one of two manual-based treatments, which 
supported the consistent and accurate application of these therapies. However, our follow-up 
study suffers at least three important limitations. We were able to retain only 65% of the 
original cohort for any follow-up assessments beyond one year, as this was an open and 
unplanned follow-up. Consequently, long-term follow-up participants represent a 
convenience sample rather than a random sample, and generalizability to the full sample is 
not appropriate. Of those who did complete a long-term follow-up assessment, 
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approximately two-fifths participated in only one follow-up interview, which precludes a 
more detailed assessment of variability in psychiatric status over time. As a result, these data 
were limited in their ability to capture events (e.g., new remissions or relapses) and record 
the timing of events with relative accuracy. Furthermore, these assessments only captured 
remission and relapse at specific points in time, rather than during more comprehensive 
windows of time. In addition, we also relied on phone interviews in some instances, which 
may have led to imprecise information, especially in terms of weight outcomes. A possible 
confounding factor is the fact that some of the study participants may have sought additional 
treatment during the follow-up period, and this information was not systematically captured 
in this follow-up.
Taken together, these findings suggest that once achieved, full remission is stable regardless 
of treatment type, as there were few relapses during the longer-term follow-up period. This 
study also suggests that, when efficacious, FBT works relatively quickly and has sustained 
effects. AFT participants made additional gains over time, but it is unclear if these 
improvements were related to late response to AFT or other factors. Nonetheless, new 
remissions during the follow-up period were few, suggesting that additional recovery during 
follow-up was unlikely. This finding is consistent with studies of adolescents and adults 
with AN with a longer duration of the disorder, for which no treatments have yet 
demonstrated substantial differential benefits. Future research is critically needed to 
investigate potential ways to enhance outcomes. Findings from the present study, keeping 
the caveats of the limitations described in mind, add support to the importance of early and 
effective intervention with adolescents with AN.25 They also highlight the challenges 
inherent to conducting longitudinal treatment studies with this patient population. There 
clearly is a need to improve the outcomes for this clinical population, and for future 
innovative research to examine, for example, new treatments or a targeted combination of 
individual and family treatments.
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Figure 1. 
Time to relapse by treatment from one-year follow-up (n=26; treatment: Wald 
chisquare=0.320, df=1, p=.57, OR = 0.443). Note: AFT = adolescent focused therapy; FBT 
= family-based treatment.
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Figure 2. 
Time to remission by treatment from one-year follow-up (n=44; treatment: Wald chi-
square=3.047, df=1, OR = 0.156, p=.081). Note: AFT = adolescent focused therapy; FBT = 
family-based treatment.
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